Background Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. Case presentation We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent. Conclusions This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions different from asthma and this opens to new therapeutic perspectives.

中文翻译：

---

用美泊利单抗治疗与嗜酸性粒细胞性胃肠炎相关的严重嗜酸性粒细胞哮喘和阿司匹林加重的呼吸道疾病：病例报告。

背景 Mepolizumab (MEP) 是第一个被批准用于治疗重度难治性嗜酸性粒细胞哮喘的抗白细胞介素 (IL)-5 附加疗法。病例介绍 我们在此描述了一名 49 岁女性的病例，她患有阿司匹林加重的呼吸道疾病 (AERD)、慢性鼻窦炎、鼻息肉和嗜酸性肠胃炎，并成功地用 MEP 治疗。治疗期间改善了一些实验室和临床项目；此外，MEP 显示可用作类固醇节约剂。结论 该病例支持美泊利单抗的使用对不同于哮喘的其他嗜酸性粒细胞疾病也有效，这为新的治疗前景开辟了道路。